ClinicalTrials.gg
RecruitingNCT07485387KoCoA cohortUpdated Mar 20, 2026

Global Collaborative Research on Establishing a Korean Cognitive Aging Cohort

An observational study in Mild Cognitive Impairment (MCI), Dementia Alzheimer Type and Chronic Pain, sponsored by Korea University. Recruiting at 1 site in South Korea. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Korea University · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.

Planned enrollment
8th of 17
180 · median 163
Started
2025
with 12 others
Observational
17 of 74
4 open now
Primary completion
2027-04
later than 15 of 23 live
Registered
72nd of 74
by date

Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 13 that started in 2025, is one of 17 observational ones, reaches primary completion later than 15 of the 23 other live ones, and was the 72nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this observational study is to learn how daily emotional stress affects cognitive function and inflammation in community-dwelling older adults aged 60 and older in Seoul, Republic of Korea. The main questions it aims to answer are:

Does daily psychological stress measured in real-time affect short-term and long-term cognitive function in older adults? Do pro-inflammatory cytokines (such as CRP, IL-6, IL-10, and TNF-α) mediate the relationship between emotional stress and cognitive decline? How do social support and social isolation influence cognitive function and inflammatory biomarkers over time?

Participants will:

Complete baseline surveys assessing depression, cognitive function, and personal characteristics Use a smartphone app to answer brief surveys about their emotions, cognitive performance, and social interactions 1-6 times daily for two weeks Wear a Galaxy Watch to track sleep quality, heart rate, and physical activity Provide blood samples for inflammatory biomarker analysis Return for follow-up assessments at 6 months and 1 year

This study is part of an international collaboration to establish a Korean cohort comparable to the U.S. Einstein Aging Study, with the aim of developing culturally tailored dementia prevention strategies.

Read the detailed description

A. Final Goal

  • This study aims to identify the interactions between physiological, psychological, social, and cultural-environmental factors that influence the maintenance and decline of cognitive function in aging of socially vulnerable older adults. By doing so, it seeks to reduce the societal burden of cognitive decline in older adults and provide a foundation for effective interventions to manage dementia risk.
  • The principal investigator's research team at Korea University's Department of Public Health Sciences and the team led by Professors Jennifer Graham-Engeland and Christopher Engeland from Penn State University (co-leaders of the Einstein Aging Study under NIH P01), aims to establish a protocol for the domestic cohort of the Einstein Study of Aging and conduct cross-national comparative research. The specific objectives are:

    1. Develop a Korean cohort protocol that is comparable to the Einstein Aging Study based on the principal investigator's existing community-based cohort studies with socially vulnerable older adults.
    2. Investigate the impact of real-time psychological stress (Ecological Momentary Assessment; EMA) on real-time and long-term cognitive function and examine the mediating effects of pro-inflammatory cytokine biomarkers through data collection in Korea.
    3. Compare Korean older adult data with the U.S. Einstein Study panel to study the influence of annual levels of social support and isolation on cognitive function and biomarkers, exploring the moderating effects of socio-environmental and cultural factors.
  • Through this research, the principal investigator and international collaborators aim to utilize their expertise in real-time daily emotional and cognitive function measurements and inflammatory biomarker protocols. By integrating psychological research methodologies, the study seeks to elucidate the biological-neuropsychological mechanisms of how emotional stress impacts neuroinflammation and cognitive regulation in older adults. This will establish a foundation for developing dementia prevention and cognitive rehabilitation programs tailored to the Korean cultural context.

B. Research Design and Overview

  1. Korean Cohort Design that is comparable with the Einstein Aging Study

    • The study adopts the Burst Cohort Design utilized by the U.S. Einstein Aging Study (EAS) for longitudinal analysis. To explore causal relationships and the role of mediators, a minimum of three repeated measurements-baseline, six-month follow-up, and one-year follow-up-will be conducted.
    • The Burst Cohort Design involves short-term (daily) and long-term (annual) assessments. Daily changes, such as emotional states and cognitive performance, will be captured via mobile app-based surveys and stress biomarker sampling over two weeks. Long-term changes will be assessed through annual follow-ups.
  2. Participant Recruitment and Incentives

    • Following IRB approval, socially vulnerable older adults (recipients of social welfare support due to economic poverty and social isolation) will be recruited through the Seongbuk Senior Welfare Center in Seoul, Republic of Korea. Training sessions on smartphone EMA will be provided as part of smartphone classes. Participants will receive tokens of appreciation and dementia prevention seminar opportunities.

      1) Participant Selection Criteria

    • Inclusion: Community-dwelling older adults aged 65 or above.
    • Exclusion: Individuals diagnosed with dementia or those with sensory, cognitive, or physical impairments that hinder survey and EMA participation.

      2) Two-Week EMA Protocol

    • During the two-week intensive survey period, baseline surveys will assess depression, mild cognitive impairment, and other participant characteristics. Daily changes in emotional state, cognitive function, and social interactions will be measured via smartphone-based EMA surveys conducted 1-6 times daily.
    • EMA minimizes recall and response biases, enabling precise quantification of intra-individual changes. Custom apps incorporating voice-assisted surveys and integration with Galaxy watch for sleep quality, heart rate variability, and physical activity data will be used, alongside cognitive tasks from the EAS protocol.

      3) Pro-Inflammatory Cytokine Signaling Measurement

    • In collaboration with Korea University Anam Hospital, clinical diagnosis and biomarker collection for cognitive impairment will be conducted. Serum samples will be centrifuged within one hour and stored at -80°C.
    • The samples will be sent to Penn State for analysis using the EAS protocol, targeting CRP, IL-6, IL-10, and TNF-α markers via multiplex bioassays. Additional cortisol ELISA and ApoE genetic variation analyses will be performed.

C. Expected Impact and Merit to the society

  1. Utilization Plans

    ① Policy and Program Development:

    • Insights from the study's findings on the bio-psycho-social mechanisms of cognitive decline in aging can inform policies and interventions for dementia prevention and management in a rapidly aging society.

      • Advancement of National Dementia Research:
    • Through international collaboration, the study will enhance methodologies and content for national cognitive aging and dementia research, leveraging the extensive experience of the Einstein Aging Study. Also, the current study will provide evidence for optimizing dementia prevention-related health services for socially vulnerable older adults.
  2. Anticipated Merits

    • Scientific and Technological Merits:

      • The study will provide a foundation for innovative elderly care models, linking digital sensing technologies with cognitive health monitoring. It could support the development of remote dementia prevention and management services for community and residential care settings.

        • Economic, Industrial, and Social Merits:
      • By understanding multidimensional mechanisms accelerating cognitive aging, the study will contribute to the integration of family and community-based elderly care, improvement in dementia diagnosis and prevention programs, reduction in family caregiving burdens, and enhancement of societal quality of life.
03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Dementia Alzheimer Type
  • Chronic Pain
  • Depression - Major Depressive Disorder

Keywords

  • mild cognitive impairment
  • dementia
  • chronic pain
  • depression
  • cognitive aging
  • longitudinal cohort
  • digital biomarkers
  • dementia biomarkers
  • behavioral phenotyping
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study targets community-dwelling older adults aged 60 and older in Seoul, Republic of Korea. Participants are recruited from the Seongbuk Senior Welfare Center and Gangbuk Municipal Senior Welfare Center.

Seongbuk-gu and Gangbuk-gu are districts with higher proportions of older adults and elevated chronic disease rates compared to other areas in Seoul, making them regions of interest for aging research.

The study population includes older adults living independently in the community who utilize local senior welfare center services. By recruiting from these districts, the study aims to generate evidence for developing effective dementia prevention strategies applicable to community-based settings in Korea.

Participants must be Samsung Galaxy smartphone users with sufficient cognitive ability to engage with ecological momentary assessment (EMA) protocols. Exclusions: dementia diagnosis, severe sensory impairments, or health conditions preventing participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 60 or older residing in the Republic of Korea
  • Samsung Galaxy smartphone users capable of using smartphone applications
  • Sufficient cognitive ability to understand and follow research instructions ( score of 21 or above)
  • For individuals who do not meet the cognitive criteria, those who understand the study procedures and provide along with their legal guardian

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of dementia at baseline
  • Severe visual or hearing impairments that prevent participation in psychological assessments
  • Illiteracy that prevents participation in cognitive testing
  • Less than 80% compliance with the 2-day preliminary EMA protocol (one additional attempt allowed after re-training)
  • Current alcohol or substance abuse
  • Inability to ambulate or psychiatric conditions that prevent survey participation
  • Currently undergoing cancer treatment or received chemotherapy within the past 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Community-Dwelling Older Adults in Seoul

    Community-dwelling older adults aged 60 and older recruited from the Seongbuk Senior Welfare Center in Seoul, Republic of Korea. Inclusion criteria: Adults aged 60 or older residing in Korea; Samsung Galaxy smartphone users; MMSE score of 21 or above; those not meeting cognitive criteria may participate with legal guardian consent. Exclusion criteria: Dementia diagnosis at baseline; severe visual or hearing impairments; illiteracy; less than 80% compliance with 2-day preliminary EMA protocol; alcohol or substance abuse; inability to ambulate or psychiatric conditions preventing participation; current cancer treatment or chemotherapy within past 6 months. This is a prospective observational cohort. Participants complete baseline assessments, then a two-week EMA period using a smartphone app for daily emotions, cognition, and social interactions. Galaxy Watch monitors sleep, heart rate, and activity. Blood samples collected for inflammatory biomarkers. Follow-ups at 6 and 12 months.

06

What researchers measure

Primary outcomes

  1. Incident MCI and Dementia Diagnosis

    Incident mild cognitive impairment (MCI) and dementia diagnoses will be identified through clinical diagnosis during the study periods and linkage with the National Health Insurance Service (NHIS) database in Korea. This administrative data linkage enables long-term tracking of cognitive outcomes beyond the active study period.

    Time frame: baseline, 6-month, 1-year, 5-year and 10-year follow-up

  2. SNSB-2 Composite Score

    Composite score from the Seoul Neuropsychological Screening Battery-2 (SNSB-2), a standardized neuropsychological assessment covering attention, language, visuospatial function, memory, and executive function domains (Standardized composite z-score).

    Time frame: Baseline and 12 months

  3. Wechsler Memory Scale Score

    Memory function assessed using the Wechsler Memory Scale (Index score (points)).

    Time frame: Baseline, 6 months, and 12 months

  4. Block Design Subtest Score

    Visuospatial constructional ability assessed using the Block Design subtest from the Wechsler Adult Intelligence Scale (WAIS) in Scaled score (points).

    Time frame: Baseline, 6 months, and 12 months

  5. EMA Daily Cognitive Task Performance

    Daily cognitive performance measured via smartphone-based ecological momentary assessment (EMA) using the Mobile Monitoring of Cognitive Change (M2C2) platform during the 2-week intensive period. Performance is assessed as accuracy (proportion correct) and reaction time on cognitive tasks.

    Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months

  6. Plasma Phosphorylated Tau (p-tau) Level

    Plasma concentration of phosphorylated tau, a biomarker of tau-related neurodegeneration in Alzheimer's disease.

    Time frame: Baseline, 6 months, and 12 months

  7. Pro-Inflammatory Cytokine Composite Score

    Serum levels of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-α) will be measured using a multiplex ELISA. A cytokine composite score will be calculated using the factor analysis.

    Time frame: Baseline, 6 months, and 12 months

  8. Plasma Amyloid Beta (Aβ) Level

    Plasma concentration of amyloid beta, a biomarker associated with Alzheimer's disease neuropathology (pg/mL).

    Time frame: Baseline, 6 months, and 12 months

  9. ApoE Genotype

    Apolipoprotein E (ApoE) genetic variation determined by DNA analysis. Participants will be classified as ApoE ε4 carriers or non-carriers.

    Time frame: Baseline

Secondary outcomes

  1. EMA Daily Negative Affect

    Daily negative emotional states measured via smartphone-based EMA surveys administered 1-6 times per day during the 2-week intensive period (0-100 scale).

    Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months

  2. EMA Daily Positive Affect

    Daily positive emotional states measured via smartphone-based EMA surveys administered 1-6 times per day during the 2-week intensive period. The scores are assessed by a mean score (0-100 scale).

    Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months

  3. Depressive Symptoms

    Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) at each follow-up visit. Yes/No coding will be used to assess reports of depressive symptoms.

    Time frame: Baseline, 6 months, and 12 months

  4. EMA Daily Social Interaction Frequency

    Frequency of daily social interactions measured via smartphone-based EMA surveys during the 2-week intensive period. Unit of Measure: Number of interactions per day

    Time frame: Daily during 2-week EMA period at baseline, 6 months, and 12 months

  5. Daily Sleep Quality

    Sleep quality continuously monitored using Galaxy Watch during the 2-week EMA period, including total sleep time and sleep efficiency.

    Time frame: Continuous during 2-week EMA period at baseline, 6 months, and 12 months

  6. Daily Heart Rate Variability (HRV)

    Heart rate variability continuously monitored using Galaxy Watch during the 2-week EMA period.

    Time frame: Continuous during 2-week EMA period at baseline, 6 months, and 12 months

  7. Daily Physical Activity Level

    Physical activity continuously monitored using Galaxy Watch accelerometer during the 2-week EMA period (steps per day).

    Time frame: Continuous during 2-week EMA period at baseline, 6 months, and 12 months

  8. Serum C-Reactive Protein (CRP) Level

    High-sensitivity C-reactive protein measured from serum samples as a marker of systemic inflammation (mg/L).

    Time frame: Baseline, 6 months, and 12 months

Other outcomes

  1. Serum Cortisol Level

    Cortisol level measured from serum samples using enzyme-linked immunosorbent assay (ELISA) (nmol/L).

    Time frame: Baseline and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. According to the informed consent approved by the Institutional Review Board (IRB), participants agreed that their data would only be used by the authorized research team. Sharing IPD with external researchers was not included in the consent process, and doing so would violate the terms of consent and participant privacy protections.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 24 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Mar 20, 2026
StartActual
Apr 1, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Dec 31, 2037
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485387
Lead sponsor
Korea University
Responsible party
Sunmi Song (Research Professor, Korea University) — Principal investigator
First posted
Mar 20, 2026
Start date
Apr 1, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Dec 31, 2037 (estimated)
Last update
Mar 20, 2026

Study contacts

Sunmi Song, PhD
Contact
sunmi.song0715@gmail.com
+82232904439
Sunmi Song
principal investigator · Korea University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion